Omeros (OMER) EBITDA Margin (2010 - 2026)
Omeros recorded quarterly EBITDA Margin of 176.09% in Q1 2026, down 132.72% quarter-over-quarter from 75.67% in Q3 2021.
Omeros' EBITDA Margin history runs 13 years deep, the most recent figure standing at 176.09% for Q1 2026.
- In Q1 2026, EBITDA Margin changed N/A year-over-year to 176.09%; the TTM figure through Mar 2026 stood at 153.15% (up 5074.0% YoY), while the FY2020 annual figure was 187.04%, down 11148.0% from the prior year.
- EBITDA Margin came in at 176.09% for Q1 2026 at Omeros, down from 75.67% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 176.09% in Q1 2026 to a low of 176.09% in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | -176.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -176.09% |
| Sep 30, 2021 | -75.67% |
| Jun 30, 2021 | -99.20% |
| Mar 31, 2021 | -166.61% |
| Dec 31, 2020 | -350.57% |
| Sep 30, 2020 | -147.29% |
| Jun 30, 2020 | -246.08% |
| Mar 31, 2020 | -123.34% |
| Dec 31, 2019 | -87.46% |
| Sep 30, 2019 | -55.14% |
| Jun 30, 2019 | -54.02% |
| Mar 31, 2019 | -111.78% |
| Dec 31, 2018 | -106.89% |
| Sep 30, 2018 | -856.60% |
| Jun 30, 2018 | -2,036.01% |
| Mar 31, 2018 | -1,892.57% |
| Dec 31, 2017 | -120.28% |
| Sep 30, 2017 | -34.55% |
| Jun 30, 2017 | -83.72% |
| Mar 31, 2017 | -123.11% |
| Dec 31, 2016 | -152.13% |
| Sep 30, 2016 | -123.68% |
| Jun 30, 2016 | -126.07% |
| Mar 31, 2016 | -276.84% |
| Dec 31, 2015 | -297.02% |
| Sep 30, 2015 | -611.26% |
| Jun 30, 2015 | -523.38% |
| Mar 31, 2015 | -4,811.60% |
| Dec 31, 2014 | -11,507.22% |
| Sep 30, 2014 | -8,564.02% |
| Jun 30, 2014 | -39,980.00% |
| Mar 31, 2014 | -16,642.00% |
| Dec 31, 2013 | -1,091.72% |
| Sep 30, 2013 | -7,076.53% |
| Jun 30, 2013 | -9,708.57% |
| Mar 31, 2013 | -957.90% |
| Dec 31, 2012 | -488.57% |
| Sep 30, 2012 | -936.91% |
| Jun 30, 2012 | -559.57% |
| Mar 31, 2012 | -594.59% |
| Dec 31, 2011 | -892.48% |
| Sep 30, 2011 | -659.78% |
| Jun 30, 2011 | -458.10% |
| Mar 31, 2011 | -528.01% |
| Dec 31, 2010 | -876.74% |
| Sep 30, 2010 | -2,948.82% |
| Jun 30, 2010 | -1,536.02% |